All 39 STAT6-targeting programs pursue intracellular modulation rather than upstream IL-4/IL-13 cytokine blockade. The landscape divides into 18 inhibitors, 12 degraders, and 9 gene/RNA programs, with gene therapy concentrated entirely in oncology.

Only 2 of 39 programs have reached clinical stage. Kymera's KT-621 is the sole dermatology asset in clinic, with Phase 1b data showing ~63% EASI reduction and ~40% pruritus improvement in open-label results. The BROADEN2 Phase 2b trial positions Kymera to establish the efficacy benchmark before any competitor reaches the clinic.

Degraders have fewer programs than inhibitors (12 vs 18) but hold the only clinical proof in dermatology. Biotech dominates degrader development, with 6 of 9 dermatology programs. No pharma-originated degrader programs exist, suggesting big pharma views TPD as a platform to acquire rather than build.

65% of dermatology programs target oral delivery, converging on the "dupilumab-in-a-pill" thesis. Pure topical approaches are entirely absent, representing white space for sponsors targeting mild-to-moderate segments or safety-focused positioning.

23 competitor programs sit in the "PD-validated but preclinical" quadrant, years behind KT-621's clinical data. 14 programs lack PD readouts entirely, facing both mechanism and execution risk before reaching the clinic.